Project Grant R01CA298345
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $544K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...
- This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc., a project grant of $647,147 on August 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate keratinocyte signaling mechanisms in chemotherapy-induced peripheral neuropathy. The research addresses how keratinocytes—the primary cell type of the epidermis—drive neuropathic pain in patients receiving chemotherapy. Painful peripheral neuropathy occurs in up to 80 percent of chemotherapy...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Oregon Health & Science University $657,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a multiscale approach to controlling cellular interactions in premalignant tissues. The project aims to use physical science methods to manipulate interactions between multiple cell types in precancerous tissues to restore normal tissue function. The recipient will...
- The National Cancer Institute awarded Thomas Jefferson University $312,363 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess the feasibility of a remotely-delivered Tai Chi intervention for older gastrointestinal cancer patients experiencing chemotherapy-induced peripheral neuropathy (CIPN). The study addresses CIPN—characterized by numbness, tingling, and pain that impairs physical function and elevates fall risk—in patients aged 65 and above. The research...
- The National Cancer Institute awarded Adventhealth Orlando $176,256 on May 6, 2026, under the Cancer Research Manpower program (CFDA 93.398) to investigate the relationship between dietary interventions and chemotherapy-induced peripheral neuropathy (CIPN) across multiple cancer types. The funded work characterizes the association between diet and CIPN incidence in patients receiving platinum-based chemotherapies, leveraging the NCI-sponsored Exercise and Nutrition Interventions to Improve...
- The National Cancer Institute awarded Oregon Health & Science University $1,042,004 on March 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a microphysiological bone metastasis-on-a-chip platform that models prostate cancer metastasis into vascularized and innervated bone tissue. The research platform incorporates a mineralized, osteocyte-embedded bone matrix supporting active osteoclast and osteoblast remodeling, perfusable pericyte-supported vasculature to...
- The National Cancer Institute awarded Oregon Health & Science University $640,113 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop multifunctional ultrasound-responsive nanoparticles (URNs) for improved immunotherapy of melanoma. The project addresses the challenge that approximately 50 percent of melanoma patients do not respond to immune checkpoint inhibitor therapies due to immunosuppressive tumor microenvironments. The funded work...
- The National Institute of Neurological Disorders and Stroke awarded Temple University $2,470,369 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate a cannabidiol (CBD) nanoemulsion formulation, SRIN-009, for treating chemotherapy-induced peripheral neuropathy (CIPN). The project addresses CIPN, a debilitating adverse effect affecting up to 75 percent of patients receiving certain chemotherapy regimens, characterized by pain,...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded Providence Health & Services – Oregon $1,431,420 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct spatiotemporal molecular elucidation of radiation-induced tumor microenvironment remodeling to enhance immunotherapy in head and neck cancer. The award funds research into neoadjuvant immunoradiotherapy combining checkpoint inhibition with hypofractionated...